Press Releases Kiora Pharmaceuticals, Inc.

Equities

KPRX

US49721T3095

Delayed Nasdaq Other stock markets 13:14:54 2024-05-23 EDT			5-day change	1st Jan Change
0.5455 ^USD	+1.02%		-6.19%	+4.42%

05-10	Earnings Flash (KPRX) KIORA PHARMACEUTICALS Posts Q1 Revenue $16M	MT
03-25	Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences	05-20	NE
Kiora Pharmaceuticals Reports First Quarter Results, Update on Pipeline of Drugs Targeting Retinal Disease	05-13	AQ
Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease	05-10	NE
Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference	05-08	NE
Kiora Pharmaceuticals Reports Additional Clinical Data for KIO-301 Showing a Statistically Significant Increase in Brain Activity in the Visual Cortex in Patients with Retinitis Pigmentosa	05-06	NE
Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases, Approval Granted to Initiate Clinical Validation Study	04-12	AQ
Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study	04-11	NE
Kiora Pharmaceuticals to Present at Upcoming Investor Conferences	04-05	NE
Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting	03-28	NE
Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases	03-25	NE
Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye	03-08	NE
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million	01-31	NE
Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clinical Development, Regulatory and Commercial Milestones, Plus Commercial Royalties	01-31	NE
Breaking ground in vision restoration: Kiora Pharmaceuticals reveals promising results with KIO-301	11-17	AQ
Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa	11-09	NE
AAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis Pigmentosa	11-04	NE
Kiora Pharmaceuticals to Participate in the Lytham Partners Fall 2023 Investor Conference	23-10-16	NE
Kiora Pharmaceuticals Receives Investigational New Drug Application Approval to Expand Phase 1b Study of KIO-301 in Inherited Retinal Diseases; To Enroll Patients with Choroideremia and Additional Patients with Late-Stage Retinitis Pigmentosa	23-10-03	NE
Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years	23-09-21	NE
Kiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis Pigmentosa	23-09-18	NE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Kiora Pharmaceuticals, Inc.

Equities

KPRX

US49721T3095

Press Releases

Filters